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THESIS SUMMARY
Cardiovascular disease, and more specifically Myocardial Infarctions, are detrimental to
health and have long term effects on the body. MIs affect between 900,000 and 1,000,000
people in the U.S. each year. After an MI, the body goes into a process of attempting to repair
the heart, and in doing so activates FAP and MMPs. Fibroblast Activation Protein (FAP) is an
integral membrane serine protease whose expression is elevated on activated fibroblasts
during wound healing processes. Matrix metalloproteinases (MMPs) play an important role in
adverse remodeling following myocardial infarction (MI) through altering extracellular matrix
form and function. However, whether and to what degree FAP alters MMP activation and
therefore how relevant it is to post-MI remodeling is unclear.
Cardiovascular tissue was collected 14 days post-MI and was digested for cell separation
and collection. Fluorescent staining and microscopy were then used in order to detect FAP
localization. In order to quantify the amount of FAP per sample, BCA assays and western blots
were used. The blots were analyzed for the presence of FAP within the samples. The
significance of having FAP present in the MI samples and absent in the control samples, is that a
link can be made between post-MI remodeling and FAP activation.
The project involved optimization of procedures which qualitatively and quantitatively
validated that FAP is produced by fibroblasts from infarcted hearts. A variety of techniques
were employed including western blots, fluorescent staining, and BCA assays. Through this
project and working in the lab, I learned about many cellular processes and to think critically
about how and why experiments worked or did not.
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INTRODUCTION
Cardiovascular Disease
Cardiovascular disease is an extremely prevalent and costly disease, as it is the number
one cause of death in the US. In 2006 alone, cardiovascular disease cost the U.S. over $400
billion from direct healthcare spending and lost-productivity (Mensah & Brown, 2007).
According to a study conducted by the CDC in 2012, 26.6 million adults in the US, or 11.6% of
the adult population, had been diagnosed with cardiovascular disease (CDC, 2015). Each year in
the U.S., roughly 635,000 people have a first-time heart attack and about 300,000 have
recurrent heart attacks (Mozaffarian D, 2015).
A myocardial infarction (MI), also known as a heart attack, occurs when blood stops
flowing to an area of the heart causing necrosis and scarring of the tissue in that area. This kind
of scar is different from a scar on the skin because cardiomyocytes, the contractile cells within
the heart, are considered to be terminally differentiated, meaning they cannot be regenerated
(Cleutjens, 1999). Through this process of wound healing, the death of myocytes leads to
collagen degradation and re-deposition in the extracellular matrix, which in turn leads to
stiffening of the heart walls. All of this combined is considered cardiac remodeling, meaning
that the infrastructure of the cells and the matrix within the heart adjusts to attempt to
accommodate the reduction in cardiomyocytes post-MI. Cardiac remodeling is the body’s way
of trying to fix itself, but it unfortunately goes too far and ultimately remodels so much that the
heart is unable to function normally and the person enters heart failure.
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Figure 1. Image of infarct over time. Cross sectional image of a normal heart vs. an
infarcted heart immediately post-MI as well as after some time. Over time, the LV wall
thinning and heart dilation become very apparent, and affect the function of the
myocardium. (Goldthwaite, Jr., 2016)
The diagram above shows what happens over time to a normal heart after the trauma
of an MI. After an MI, myocytes within the infarcted area die and activated fibroblasts deposit
collagen, forming the scar tissue in the affected area which stiffens the heart wall adding extra
stress to the functioning myocardium. As a way to compensate for the reduced function, the
ventricle dilates in order to allow more blood in the chamber at a time.
This scar tissue formation is partially due to the process beginning with FAP activation
after the MI occurs. Once FAP is activated, it is thought that it helps to increase MMP activity,
thereby initiating degradation of the extracellular matrix of the heart. If this is the case, FAP
may play a larger role in cardiovascular disease than initially thought.
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Fibroblasts and their role in disease
Fibroblasts are cells that produce and secrete different types of structural proteins
including collagen, which helps to maintain the ECM homeostasis (Goldsmith, et al., 2013).
Fibroblasts are found in a variety of organs and are responsible for turning over the ECM and
churning out new structural proteins as a form of maintenance for the cells. Fibroblasts are
critically important in wound healing as well, and are activated to replicate and increase
production of collagen after an injury.

Figure 2. Cardiac Fibroblasts. Diagram showing products of cardiac fibroblasts,
which affect the structure and function of the heart. (Fan, et al., 2012)
Although fibroblasts are found in multiple tissues, they are especially important in
infarct healing. Fibroblasts make up the largest portion of cells within the heart, accounting for
roughly 40-60% of the total number of cells (Baum & Duffy, 2011). Cardiac fibroblasts produce
molecules that make up the extracellular matrix(ECM), such as structural proteins like collagen.
Unlike cardiomyocytes, cardiac fibroblasts are not terminally differentiated, so they are able to
divide while they continue to produce ECM. The production of collagen is kept in balance by
matrix metalloproteinases (MMPs), which are able to degrade proteins in the ECM, including
collagen. The balance between collagen deposition by fibroblasts and degradation by MMPs is

10

very delicate and an MI can wreak havoc on this balance. When an MI does happen, the
fibroblasts create collagen and structural proteins unregulated, which causes a build-up of
those products and ultimately leads to fibrosis (Fan, et al., 2012).
Fibroblasts and MMPs have an important relationship in keeping the ECM at a proper
balance. It is vitally important that the heart have enough extracellular structure in order to
keep the myocytes in place, but not too much so that the myocytes lose function due to
fibrosis. During this cardiac remodeling, fibroblasts transition into myofibroblasts which are
cells with characteristics of both fibroblasts and smooth muscle cells (Van Den Borne, et al.,
2010). Like fibroblasts, myofibroblasts function in wound repair by degrading and secreting
collagen. Ideally, these myofibroblasts would quickly mobilize around the injured tissue to
initiate wound healing, then would cease function by undergoing apoptosis. Like fibroblasts
though, if they persist within the surviving myocardium their continuous remodeling ultimately
leads to cardiac fibrosis and heart failure (Santiago, et al., 2010; Tillmanns, et al., 2015). When
fibroblasts transition into myofibroblasts, they express α-smooth muscle actin (SMA) which
fortunately can be stained and visualized using a confocal or other light microscope (Tillmanns,
et al., 2015).

11

Matrix Metalloproteinases
Cardiovascular remodeling post-MI is associated with size and shape changes of the left
ventricle (LV), wall stiffening, and LV decreased function. This tissue remodeling is due to
increased presence and activity of MMPs, which are responsible for proteolysis of the ECM.
While under normal conditions MMP activity is strictly controlled by Tissue Inhibitors of
MMPs (TIMPs), under pathologic conditions such as post-MI, MMP activity is increased and
negatively impacts the heart’s ability to heal and resume normal functioning (Purcell, et al.,
2014). At the organ level, MMPs affect the remodeling of the LV including wall thinning and
chamber dilation, while TIMPs oppose the effects of the MMPs by weakening the area of the
infarct and preventing LV dilation in order to maintain function (Purcell, et al., 2014; St. John
Sutton & Sharpe, 2000). At the level of the fibroblast, MMP regulation by TIMP refers to the
degradation and deposition of new extracellular matrix materials, especially collagen (Li, et al.,
2000). There has been some promising research around modifying the balance of MMP and
TIMP by increasing the amount of TIMP present, therefore reducing the activity of MMPs. The
results of these studies showed that the post-MI remodeling was reduced and some heart
function and geometry were preserved compared to the controls (Zavadzkas, et al., 2014).
While exogenous MMP inhibition has been researched as a potential therapeutic option
to prevent post-MI remodeling and subsequent heart failure, no method has been approved for
clinical application because of the limited amount that can be utilized due to side effects
attributed to the wide tissue distribution of MMPs (Purcell, et al., 2014). MMPs can degrade a
variety of proteins within the ECM, particularly collagens, but their interactions with other ECM
components are less well defined. Because MMPs can be so destructive to the ECM following
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an MI, research into the regulation of myocardial MMP expression and activity is being
conducted to find a suitable treatment option (Spinale, et al., 2000).

Figure 3. Flowchart of post-MI remodeling mechanisms. Diagram of the activation,
upregulation/facilitation, and inhibition mechanisms that occur post-MI in the heart.
(Ma, et al., 2014)
This continued remodeling and expansion of the ECM compromises function and
changes the overall geometry of the left ventricle. As shown in Figure 4, an increase in
myofibroblasts causes an increase in structural ECM due to collagen deposition, which is
remodeling on a molecular level. Enough remodeling at this molecular level will cause
remodeling on a larger scale causing the geometry of the heart to change, depicted in the
diagram as the LV remodeling. All of this alteration, whether small scale or large, leads to added
stress on the myocardium and eventually heart failure. Since the first step in the cycle after the
MI is myofibroblast activation, it is important to determine if a target can be identified here to
prevent the cycle of remodeling at the start.
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Fibroblast Activation Proteins and Expression Post-MI
Fibroblast Activation Protein (FAP) is an integral membrane serine protease whose
expression is elevated on activated fibroblasts during wound healing processes (Tillmanns, et
al., 2015). FAP has been shown to cleave denatured as well as native collagens. Collagen is an
important component of extracellular matrix within the heart and its turnover by MMPs is
important in adverse remodeling associated with many forms of cardiovascular disease. FAP is
unlike MMPs in that it has no endogenous inhibitor like MMP does, so without anything to
induce apoptosis FAP could continue remodeling long after it needs to.

Figure 4. FAP in Post-MI Remodeling- Working Model. FAP not only degrades ECM but
may also contributes to MMP activation mechanism and is induced within post-MI
fibroblasts.
After an MI, FAP is activated and is thought to increase MMP activity which would
perpetuate the disadvantageous tissue remodeling, so FAP could be a novel target for inhibition
to prevent tissue remodeling. A study was done on rats to identify FAP activity post-MI, and it
was found that FAP was only expressed in actively remodeling tissue. The researchers were
then able to conclude that fibroblasts were active in the same remodeling tissue, and that FAP
could be used as a marker for activated fibroblasts (Tillmanns, et al., 2015).
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The overarching purpose of this study was to test the hypothesis that FAP can activate
proMMPs, such as proMMP-2, and thus provide a novel initiation mechanism for MMPmediated post-MI remodeling. Little is known about the function of FAP in the heart or what
role it may play in activating other proteins such as MMPs. The goal of my project was to
develop methods for the quantification and visualization of FAP on cardiac fibroblasts. This
project involved the optimization of procedures which qualitatively and quantitatively validated
that FAP is produced by fibroblasts from infarcted hearts.

15

METHODOLOGY
Overview
To evaluate the expression of FAP in fibroblasts and be able to determine differences in
FAP expression associated with disease, fibroblasts were obtained from a porcine myocardial
infarct (MI) model. Formation of the MI was accomplished as described below and primary
adult fibroblasts isolated from the heart tissue. Protein extracts were prepared from MI and
control (animals with no MI) to be used in western blots or cells were plated in tissue culture
dishes for staining.

Porcine MI Model and Isolation of Myocardial Fibroblasts
Ligation of obtuse marginal arteries 1 and 2 was used to induce MI in pigs (Etoh, et al.,
2001). Heart function was monitored for 14 days after which the animals were sacrificed and a
portion of the left ventricle containing the infarct region as well as tissue from control animals
was obtained. The LV free wall encompassing the MI region as well as referent controls (n=5)
was used for fibroblast isolation by enzymatic digestion (Liberase TM, Roche) (Goldsmith, et al.,
2016).
The fibroblasts were isolated using the Adult Pig Cardiac Fibroblast Isolation protocol.
Fibroblasts were cultured in either low glucose DMEM or high glucose DMEM. The digestion
solution used contained 60 ml KHB (sigma k3753) and one aliquot of Liberase TM (4.2
mg/aliquot)/ 9 grams of tissue (Roche 05401127001). The tissue was placed in a solution of PBS
containing penicillin and streptomycin. The tissue was then placed in a 100 mm dish, was
weighed, and minced into small pieces. The pieces of tissue were then transferred to a 125 ml
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flask. The tissue was washed 4 times with cold KHB. Ten millilters of the digestion solution was
then added to the tissue, and the flask was placed in a shaking water bath for 20 minutes at
37˚C at a fast enough speed that the solution is swirled in the flask. The flask was then vortexed
for about 15 seconds to help break up the tissue more. The supernatant was then poured into a
tube a centrifuged at a speed of 800 RPM for 8 minutes at room temperature in order to
separate the cells from the digestion solution. The pellet that formed was then re-suspended in
15 ml of fresh media and placed in a T75 flask. This process was repeated until the tissue was
nearly gone, which was about 6 digestions. The media was replaced roughly every 48 hours
until cells were confluent.
Fibroblasts were maintained in DMEM supplemented with 10% fetal bovine serum and
antibiotics (all purchased from Sigma), and in all studies cells were used prior to the 6th passage
(Goldsmith, et al., 2016).

Table 1.
Antibiotic Concentrations used in DMEM
Antibiotic concentrations used in
DMEM
Penicillin G
Streptomycin
Amphotericin B
Gentamicin

Concentration
100 µl/ml
100 µg/ml
1 µg/ml
10 µg/ml

During the project, the fibroblasts were switched from DMEM containing low glucose
concentration to DMEM containing high glucose concentration in an attempt to improve
growth
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Fluorescence Microscopy to Detect FAP Localization
Immunofluorescent staining was used to assess FAP localization. Prior to starting the
staining procedure, 50,000 fibroblasts were plated onto collagen-coated cover slips and
cultured for roughly a week until confluent. Coverslips were fixed with 2% paraformaldehyde
for 30 minutes at room temperature and stored at 4˚ C until used.
First, the coverslips were washed briefly with 1X Phosphate Buffered Saline Tween-20
(PBST) then the PBST was removed and the cells were permeabilized by pipetting 200 µl of 0.5%
Triton-X 100 in PBS onto the coverslips. The cells were then incubated for 5 minutes at room
temperature. The cells were washed again in PBS and incubated with 250 µl of 10 mg/ml Bovine
Serum Albumin(BSA) in PBS for 1 hour at room temperature to prevent non-specific binding of
antibodies to the cells. While the cells were incubating in the BSA solution, the primary
antibody solutions were prepared. Several different primary antibodies were tested and they
are listed below.

Table 2.
Primary Antibody Information for Staining
Primary
company
Catalog #
company
Antibodies
location
Rabbit
polyclonal
Ab 53066
Abcam
Cambridge, USA
IgG anti-FAP
Rabbit
Polyclonal
Ab 28246
Abcam
Cambridge, USA
IgG anti-FAP
Rabbit
Monoclonal
Ab 207178
Abcam
Cambridge, USA
IgG anti-FAP
Note: Specific antibody concentrations used will be noted in Tables 5 and 7
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After the hour blocking step, cells were washed and the primary antibody (or BSA in PBS
for the control group) was added and allowed to incubate overnight at 4˚C. After the cells had
gone through the primary antibody step, they were washed and the secondary antibodies were
added. Specific secondary antibodies used in this study are listed below.

Table 3.
Secondary Antibody Information for Staining
Secondary
Company
Catalog #
Company
Antibodies
Location
Molecular
Alexa Fluor
Eugene,
A-11008
Probes 488 Gt⍺Rb
Oregon,USA
Invitrogen
Jackson
Cy3
Code 711-165Immuno
West grove, PA,
conjugated
152
Research
USA
Dk⍺Rb
Inc.
Jackson
Cy5
Code 111-175Immuno
West grove, PA,
conjugated
144
Research
USA
Dk⍺Rb
Inc.
Molecular
Alexa 594
Eugene,
A-11012
Probes Gt⍺Rb
Oregon,USA
Invitrogen
Note: Specific concentrations used are given in table 5. Goat (Gt), Rabbit (Rb),
Donkey (Dk).
The cells needed to be incubated in the dark once the secondary was added because the
fluorescent dye conjugated to the secondary antibody is sensitive to light. After the secondary
antibody incubation was complete, cells were washed and fluorescent Phalloidin conjugates, to
stain the actin filaments, and DAPI, to visualize the nucleus were added. Phalloidin conjugates
were used at a dilution of 1:1000 and DAPI (stock concentration at 5 mg/ml) at a dilution of
1:1000.
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Table 4.
Phalloidin Information for Staining
Phalloidin

Catalog #

Texas Red-X

T7471

Alexa Flour
488
Alexa Flour
594
Table 5.

A12379
A12381

Company
Molecular
Probes Inc.
Molecular
Probes Inc.
Molecular
Probes Inc.

Company
Location
Eugene, Oregon,
USA
Eugene, Oregon,
USA
Eugene, Oregon,
USA

Staining Protocol Differences by Trial
Trial
Treatment

1

2

3

4

Primary Antibody
Primary Antibody dilution

Ab 53066
1:100

Ab 53066
1:100

Ab 28246
1:100

Ab 207178
1:100

Secondary Antibody #1

488
Gt⍺Rb

Cy3
Dk⍺Rb

Cy5
Dk⍺Rb

488 Gt⍺Rb

Secondary Antibody #1
dilution

1:250

1:250

1:250

1:250

Secondary Antibody #2

Cy3
Dk⍺Rb

N/A

N/A

Alexa 594
Gt⍺Rb

Secondary Antibody #2
dilution

1:250

N/A

N/A

1:500

Stain #1 (for actin)

Texas
Red-X

Alexa 488

Alexa 488

Alexa 594

Stain dilution

1:1000

1:1000

1:1000

1:1000

N/A

N/A

N/A

N/A

Stain #2 (for actin)
Stain dilution

Alexa 488
Phalloidin
1:1000

Alexa 488
Phalloidin
1:1000

Note: Listed in each column is the specific treatment used in each trial. Different
dilutions of antibodies were tested in order to improve visibility without wasting
materials. The Phalloidin is a protein that binds directly to the actin.
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After 30 minutes, the cells were rinsed with PBS and mounted on 3x1 glass slides with
DABCO antifade mounting media. The slides were then ready to be viewed under the confocal
or EVOS microscopes. Under the microscope, a bright blue circle in each cell would indicate
that the nucleus had stained with DAPI, the lines crisscrossing the cell (could appear in different
colors depending on which Phalloidin as used) would indicate that the actin cytoskeleton had
stained with Phalloidin, and red punctate dots on the cell membrane or within the cell (golgi
localization) would indicate that FAP was present and that the antibodies had properly attached
to the FAP.

Protein Quantification and Western Blotting
BCA Assay
A BCA Assay is used when the determination of protein concentration within a sample is
needed. A 96-well microtiter plate with flat bottom wells must be used, and a stock solution of
BSA (1 mg/ml) is used to create a series of dilutions so that a standard curve may be prepared
(see table below). The BCA assay was carried out using the Pierce BCA kit as described below.

Table 6.
BCA Assay Stock Solution
12
Row A, Well
1
2
3
4
5
6
7
8
9
10 11
BSA (vol µL)
0
1
5 10 20 30 40 50 60 70 80 100
0
RIPA Buffer (Vol µL) 100 99 95 90 80 70 60 50 40 30 20
concentration (µg/mL) 0 10 50 100 200 300 400 500 600 700 800 1000
Note: Volume in each well is combination of BSA and RIPA in corresponding column.
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Once the microtiter plate was prepared, the Pierce Reagents A and B were mixed in a
1:50 ratio respectively and the solution should turn green upon mixing. The AB solution (200
µL) was carefully pipetted into the appropriate wells in the microtiter plate. Each experimental
sample of protein was diluted in RIPA buffer at a 1:10 ratio, then 10 µl of each sample was
added to the two corresponding wells in the microtiter plate. Once all of the samples had been
distributed, 10 µl from each BSA sample comprising the standard curve was added to the
appropriate well. Each sample, standard curve and experimental, is done in duplicate. The plate
was incubated at 60˙C for 30 minutes, then allowed to cool at room temperature for about 5
minutes. At this point, the solutions in the well turned from green to purple if there was protein
present. The plate was read using the Benchmark Microplate Reader at 562 nm. Protein
concentrations were determined using the standard curve by looking at the absorbance for the
experimental samples and what concentration that absorbance value represented.

Gel Electrophoresis and Western Blotting
Western blots consist of multiple stages including running samples of protein through a
polyacrylamide gel, transferring the protein to nitrocellulose, then treating with a series of
blocking buffer and antibodies, and detecting with Enhanced Chemiluminescence (ECL).
Western blots can also be quantitative or qualitative depending on if the protein concentration
is known and the samples are loaded in equal amounts on the gel.
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Table 7.
Antibody Information for Western Blot Protocol
Antibodies

Catalog #

company

primary

Ab 53066
Ab 28246
Ab 207178

Abcam
Abcam
Abcam

company location

Observed band size
(kDa)
90
110
95

Cambridge, USA
Cambridge, USA
Cambridge, USA
Danvers, MA,
ß Tubulin 2128
Cell Signaling
55
USA
Danvers, MA,
ß Actin 4967
Cell Signaling
45
USA
Little Chalfont,
Dk a Rb HRP
Secondary
GE Healthcare Buckinghamshire,
N/A
NA934V
United Kingdom
Note: Primary and secondary antibodies are listed in this table, along with each catalog
number, and company name and location

The protocol instructed that the samples should be taken out of the freezer to thaw on
ice while the SDS-PAGE apparatus was set up, depending on the type of gel being used. Enough
running buffer at a 1X dilution was then prepared in order to fill the tank but not overflow.

Table 8.

Western Blot Set Up Protocol Differences by Trial
Trial

Gel type
Treatment

Buffer
Marker
type
(Continued on next page)

1
4-20%
12-well
Hepes

2
4-20%
12-well
Hepes

3
Reused
from trial 2
Hepes

4
4-20% 12well
Hepes

5
Reused from
trial 4
Hepes

Rainbow

Rainbow

Rainbow

Thermostat

Thermostat
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Trial
9

10

Reused
from trial 8

Reused
from trial 9

Buffer
Hepes
Tris Acetate
Marker
Thermosta
Rainbow
Thermostat
Thermostat
type
t
Note: List of gel type used, buffer used, and marker type used by trial.

Tris Acetate

Gel type
Treatment

6
Reused
from trial
3
Hepes

7
Reused
from trial 5

8
7% trisacetate 12+2
well
Tris Acetate

Thermostat

Prior to running the samples through the gel, they were prepared in PCR tubes. First, the
chosen molecular weight marker (BioRad Rainbow or Fisher Thermostat) was added to its
labeled tube as well as the purified FAP protein to its labeled tube. Then, based on how much
protein and total liquid each well could hold, the samples of tissue were combined with a
calculated amount of water, dye, and ß-Mercaptoethanol and placed in separate PCR tubes.
Once all of the tubes were filled with the proper amounts of each sample, they were quickly
vortexed then loaded into the BIO RAD My IQ Single Color Real-Time PCR thermocycler and run
on the protein denature cycle at 95˚ for 5 minutes. Once removed, the same volume of
contents of each tube was carefully pipetted into the specified well until all samples were
added. The apparatus lid was attached with the connectors aligned black-to-black and red-tored, and connected to a power source to run at 150 v for about an hour or whenever the dye
reached the bottom of the gel.
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Table 9.
Trial 1 of Western Blot
Well #

Sample
Name
MW

Sample
(µL)
10

H2O(
µL)
0

6X dye
(µL)
0

1
2
3
FAP
2
9.5
2.5
4
5
P806 (IP)
11.5
0
2.5
6
P932 (RIPA)
11.5
0
2.5
7
P783 (IP)
11.5
0
2.5
8
P815 (RIPA)
11.5
0
2.5
9
P821 (IP)
11.5
0
2.5
10
P934 (RIPA)
11.5
0
2.5
11
P785 (RIPA)
11.5
0
2.5
12
P938 (RIPA)
11.5
0
2.5
Note: Table depicts contents of each well in the gel

ß-ME
(µL)
0
1
1
1
1
1
1
1
1
1

Table 10.
Trials 2, 3, and 6 of Western Blot
Sample
Sample H2O( 6X dye ß-ME
Well #
Name
(µL)
µL)
(µL)
(µL)
1
MW
10
0
0
0
2
3
FAP
2
16.6
3.9
1
4
5
P806 (IP)
18.6
0
3.9
1
6
P932 (RIPA)
12.5
6.1
3.9
1
7
P783 (IP)
15.6
2.7
3.9
1
8
P815 (RIPA)
4.5
14.1
3.9
1
9
P821 (IP)
14.9
3.7
3.9
1
10
P934 (RIPA)
10.2
8.4
3.9
1
Note: Table depicts contents of each well in the gel. The blot was used in trial
2, then stripped and reused for trials 3 and 6.
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Table 11.
Trials 4, 5 and 7 of Western Blot
Well #

Sample
(µL)
10

Sample Name

H2O(
µL)
0

6X dye
(µL)
0

ß-ME
(µL)
0

1
Thermostat
2
3
FAP
2
16.6
3.9
2
4
5
P806 (IP)
18.6
0
3.9
2
6
P821 (IP)
14.9
3.7
3.9
2
7
P815 (MI, RIPA)
4.5
14.1
3.9
2
8
P786 (MI, RIPA)
5.1
13.5
3.9
2
9
P934 (RCR, RIPA)
10.2
8.4
3.9
2
10
P932 (RCR, RIPA)
12.5
6.1
3.9
2
Note: Table depicts contents of each well in the gel. The blot was used in trial 4,
then stripped and reused for trials 5 and 7.
Table 12.
Trials 8, 9, and 10 of Western Blot
Trial 8

DMEM

1

MW

Sample
(µL)
20

H2O(
µL)
0

4X dye
(µL)
0

ß-ME
(µL)
0

FAP

2

24.4

9

1

Gel KRS

2
3
4
5
6
7

High Glucose
High Glucose
High Glucose
High Glucose
High Glucose
High Glucose

P815 MI
P938 MI
P816 MI
P821 RC
P932 RC
P806 RC

12.5
21.5
20.2
26.4
11.7
14.2

13.9
4.9
6.2
0
14.7
12.2

9
9
9
9
9
9

1
1
1
1
1
1

8
9
10
11

Low Glucose
Low Glucose
Low Glucose
Low Glucose

P815 MI
P938 MI
P934 RCR
P932 RCR

7.2
14.3
16.3
20.1

19.2
12.1
10.1
6.3

9
9
9
9

1
1
1
1

Note: Table depicts contents of each well in the gel. The blot was used in trial 8, then
stripped and reused for trials 9 and 10.
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Once the samples were finished running through the gel, the protein on the gel was
transferred to a sheet of nitrocellulose using a Biorad Mini Transfer. Stacked on top of a
cassette sitting in transfer buffer, a fiber pad followed by a piece of wetted whatman filter
paper then the gel followed by the sheet of nitrocellulose then another piece of wetted
whatman filter paper as well as another fiber pad were sandwiched together within the
cassette. The cassette was then placed in the transfer unit which was placed into the buffer
tank container which has been filled with transfer buffer, a stir bar, and an ice pack. It is
important to note that the cassette was placed in the unit such that the nitrocellulose faced the
red side; this is so that the protein is able to transfer to the nitrocellulose. Once the unit was
fully assembled, it was connected to the power supply set at 15 V and was left to transfer
overnight at room temperature.
Once the protein had successfully transferred from the gel to the nitrocellulose, the gel
was discarded and the blot was then treated with a series of blocking buffers and antibodies.
The blot was placed protein side up throughout the trial. First the blot was incubated in 5% milk
in TBST for 1 hour at room temperature, then was allowed to incubate in the specified primary
antibody for 1 hour at room temperature. Once the blot had gone through the primary
antibody phase, it was washed in TBST for 5 minutes, 3 times in order to remove all of the
primary antibody before moving onto the secondary antibody. The blot was then allowed to
incubate in the specified secondary antibody for an hour at room temperature. Once both
antibody phases were completed, the blot was washed in TBST again for 5 minutes, 3 times in
order to prepare for ECL detection.
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Table 13.
Western Blot Set Up Protocol Differences by Trial
Trial

Primary
Antibody
Primary
Antibody
dilution
Treatment
Secondary
Antibody
Secondary
Antibody
dilution
(Continued below)

1

2

3

4

5

Ab
53066

Ab
53066

Ab
28246

Ab 53066

Ab 53066
*saved from trial 2

1:750

1:750

1:750

1:750

1:750

Dk a Rb
HRP

Dk a Rb
HRP

Dk a Rb
HRP

Dk a Rb
HRP

Dk a Rb HRP

1:2000

1:2000

1:2000

1:2000

1:2000

6
ß-Tubulin

7
Ab28246

Trial
8
Ab 28246

Primary Antibody
Primary Antibody
1:500
1:750
1:750
dilution
Treatment Secondary
Dk a Rb
Dk a Rb
Dk a Rb
Antibody
HRP
HRP
HRP
Secondary
1:2000
1:2000
1:2000
Antibody dilution
Note: Listed in each column is the specific treatment used in each trial.

9
Ab 207178

10
ß-Actin

1:750

1:500

Dk a Rb
HRP

Dk a Rb
HRP

1:2000

1:2000

In order to complete the ECL detection, film, a film cassette, a sheet protector, and the
ECL chemicals were collected. The blot was placed in a dry container then allowed to incubate
in a 1:1 solution of the ECL chemicals for 5 minutes at room temperature. Once done
incubating, the blot was placed in the sheet protector carefully, so as to avoid bubbles between
the blot and sheet protector. The blot was then placed in the film cassette and was taken along
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with film to the dark room in order to allow the film to detect under safelight. Once in the dark
room, a piece of film with a notched corner was placed on the blot and the cassette was sealed
for a specified period of time. Once the film was done detecting, it was placed in the XOMAT
automatic film developer. Once the film exited the machine, it was fully developed and could
be exposed to light. The film should have an image of the blot with bands denoting where
proteins had migrated in the gel, and the film could be placed on top of the blot in order to
ascertain the size of each protein and therefore what the identity of the protein was. The blot
could be preserved for future use by placing it in a container filled with TBS.
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RESULTS AND DISCUSSION
Expression of FAP in Porcine Cardiac Fibroblasts Determined by Western Blotting
5 783 932 806
938 785 934 821 81

FAP

MW

Figure 5. Trial 1 Blot. Image of blot from trial 1, refer to tables 8 and 9 for volumes of
contents of each well.
In Figure 5, the purified FAP did not show up at all. This could be due to multiple factors
such as not having enough protein in the sample. The protein that did show up is not FAP,
which is known because the FAP bands would have been at 90 kDa instead of 70 kDa which is
what is visible in the blot. For the next blot, the amount of protein per well was adjusted to
ensure that enough protein was in the sample.
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934 821 815 783 932
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FAP

MW
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Figure 6. Trial 2 Blot. Image of blot from trial 2, refer to tables 8 and 10 for
concentrations of contents of each well.
A very similar protocol was followed as to what was used in Figure 5, the only thing that
was changed was the amount of protein loaded into each well. The amount of protein loaded in
the gel were altered so that there would be plenty of protein present. The protein band visible
at just below 100 kDa was
• the FAP, but that is not what is visible in the samples as denoted by
the fact that the sample protein bands are at just below 70 kDa. The primary antibody may
have been the problem because it may have stained other proteins. Changing the primary
antibody might produce the desired effect of FAP staining in the MI samples.

•

•
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934 821 815
783 932 806

FAP

MW

kDa
-- 260
-- 140
-- 100
-- 70
-- 50
-- 40
-- 35
-- 25
-- 15

Figure 7. Trial 3 Blot. Image of blot from trial 3, refer to tables 8 and 10 for
concentrations of contents of each well.
Since blot 2 (refer to Figure 6) had an accurate band size for the purified FAP sample, it
was reused with a different primary antibody and same secondary. The samples still did not
show up at the proper size, meaning that the FAP is not present within the protein bands
shown. This blot was too dirty after this trial to use again, so a new blot was needed as well as a
different antibody.
The blot from Trial 4 was used to see if Ab53066 was still usable or if it had been
denatured due to heat exposure. Thermostat markers were used instead of rainbow markers
for the MW marker because they are more sensitive. Since the blot was very dirty and it was

I

clear that absolutely no bands were visible, it was determined that the Ab53066 had been
denatured and was no longer usable.
The antibody Ab53066 was reused" from trial 1 since it had been reserved in blocking

,

buffer and stored at 4˚C. The membrane from Blot 4 was reused and incubated in the reused

32

Ab53066 and Dk a Rb HRP at 1:2000. This antibody was also deemed unusable, most likely from
incubating in blocking buffer for extended period of time.

934 821 815 783 932 806

FAP

MW

Figure 8. Trial 6 Blot. Image of blot from trial 6, refer to tables 8 and 10 for
concentrations of contents of each well.
After determining that the 53066 antibody still would not work, it was deemed
necessary to change primary antibodies. ß-Tubulin was decided on as the new primary
antibody, because it is an abundant cytoskeleton protein which should have been clearly visible
on the membrane. The membrane from Blot 3 was reused with the primary antibody ß-Tubulin
at 1:500 and secondary antibody Dk a Rb HRP at 1:2000. Blot was determined to be unusable
from multiple strippings and reprobings but it could be determined that the ß-Tubulin antibody
did not work because the purified FAP stained but nothing else did.
The blot from trial 7 was reused from Blot 5 with a new primary antibody, Ab28246 at
1:750. Blot was determined to be unusable because nothing appeared on the film, so Ab28246
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was inconclusive. To determine whether the antibody was still functional, another trial needed
to be done with the antibody on a new blot.
High Glucose

MW FAP

815 938 816
MI MI
MI

Low Glucose

821 932 806 815 938 934 932
RC RC RC MI MI RCR RCR

Figure 9. Trial 8 Blot. Image of blot from trial 8, refer to tables 8 and 12 for contents of
each well.
For this blot shown in Figure 9, a different type of gel was used because more protein
could fit in each well. Another difference in this trial was that the cells had been stored in both
high and low glucose DMEM instead of just low glucose ones like in the prior blots. The
membrane was incubated in the primary antibody Ab28246 Rb pAb to FAP at 1:750 and
secondary antibody Dk a Rb HRP at 1:2000. It was determined that the sample protein bands
visible were not consistent with the protein band in the FAP well. It is also possible that the
multiple bands in some columns could be due to loading so much protein that some nonspecific binding occurred. Since this antibody was determined to bind too tightly and not
specifically enough, a new primary antibody was needed.
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Figure 10. Trial 9 Blot. Image of blot from trial 9, refer to tables 8 and 12 for contents of
each well.
The membrane shown in Figure 10 was reused from Blot 8 with primary antibody
Ab207178 Rb mAb to FAP at 1:750 and secondary antibody Dk a Rb HRP at 1:2000. This blot
showed promise because the protein bands are visible and distinct at the correct areas of the
membrane, but was a bit overexposed so the concentrations could be altered to have a better
blot.
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Figure 11. Trial 9 Blot – Cell Signaling. Image of blot from trial 9, refer to tables 8 and 12
for contents of each well.
The membrane from Blot 9 was reprobed again using the primary antibody ß-actin Rb at
1:500 and the secondary antibody Dk a Rb HRP at 1:2000. This was done to see if an equal
amount of protein was present in each sample, and although each well shows a relatively
similar line density, it may not be accurate enough for quantitative analysis. More careful
pipette work, especially while loading the gel, could fix this.
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FAP Localization on Fibroblasts
For each of the trials, the primary antibody should recognize FAP and the secondary
antibody should recognize the primary antibody. Since the secondary antibody is conjugated to
a fluorescent dye, it already has a stain associated with it. This should show up as punctate dots
in cellular membranes, indicating that FAP is present. The phalloidin stains actin, a cytoskeletal
protein with the cell cytoplasm, while the DAPI stains the nucleus.

Figure 12. Fluorescent Staining Image from Confocal Microscope. Image of fibroblasts
from trial 1; only visible structures are the nuclei which appear as blue circles due to the
Dapi.
Trial 1 did not work, which is obvious because only the nucleus of each cell stained due
to the DAPI. The cytoskeletal proteins should have been visible as green lines crisscrossing the
cells, while the cellular membranes should have been indicated by red punctate dots where the
cell membrane should be. It was unclear whether the secondary antibody was functioning since
only the nuclei positively stained, so it was decided that the antibody should be tested again.

Trial 2 was done to see if the secondary antibody was working because it had been
unsuccessful at staining the first time. The same protocol as the first staining experiment was
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used, but there was only one experimental and control slide remaining. After viewing with one
of the supervisors, it was determined that the confocal microscope was having technical
difficulties, so viewing the slides was continued using the EVOS machine. Since the confocal
microscope was not working, no images could be captured.
Trial 3 was done using new primary and new secondary antibodies because both the
Ab53066 and Cy3 antibodies previously used were determined to be unusable. A similar
primary antibody, Ab 28246, was used, and a Cy5 secondary antibody was used instead of Cy3.
The slides were reviewed using the EVOS machine, but because the EVOS machine has a limited
number of wavelengths it can detect, the Cy5 stain was not detected. The protocol needed to
be altered to incorporate stains with wavelengths that would be detected by the EVOS. Since
Cy5 could not be detected by the EVOS machine, nothing but the nucleus stained with DAPI so
no images were collected.
For Trial 4, a new primary antibody Ab207178 Rb mAb to FAP was used. The secondary
antibodies used were 488 Gt a Rb and Alexa 594 Gt a Rb. After confirming that the secondary
antibodies used were within the wavelengths visible by the EVOS, it was determined that the
primary antibody did not recognize FAP because nothing but the nuclei stained with DAPI. Since
nothing but the nuclei were visibly stained, no images were collected. It is possible that due to
how these antibodies were produced, if they were made against a small peptide (N or C
terminus of FAP), they may not be able to recognize the intact protein. These antibodies may
work well in western blotting where FAP is denatured and the peptide sequence used to make
the antibody is exposed and easy for the antibody to recognize. This may explain why this
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antibody was able to detect FAP in denatured samples used in the western blot but not detect
FAP in the stained intact cells.
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CONCLUSION AND FUTURE DIRECTIONS
Through a series of experiments including western blots, BCA assays, fluorescent
staining of infarcted myocardial cell samples, it can be concluded that FAP is expressed in postMI cardiac fibroblasts. Before the western blots could be performed, BCA assays were
completed and analyzed in order to quantify how much of each sample needed to be loaded
into each well so that each well had an equal amount of protein. The fact that FAP is expressed
in post-MI cardiac fibroblasts can be concluded because the western blot (Figures 10) shows
that FAP is present within post-MI cardiac tissue in significant amounts, while we know that FAP
is not expressed in uninjured tissue. These western blot results are useful because they
revealed the presence of FAP, but not specifically where the FAP was located within the
fibroblasts.
Once it was concluded that FAP was present within the fibroblasts, the staining was
done in order to see where the FAP was located. While the fluorescent staining did not
specifically show FAP present in the cells, the staining results were considered inconclusive
because FAP was clearly present in the samples according to the western blot results. This is an
area which should be looked into more closely in order to develop a method for staining the
cells so that the FAP properly stains.
Other potential future research includes the development of inhibitors that block FAP
activity as well as optimization of procedures. An FAP inhibitor could be incredibly useful in
preventing or reducing cardiac remodeling by regulating MMP activity post-MI. Along with an
FAP inhibitor, there could be other research done to provide new therapeutic tools targeted at
FAP and the mechanism of cardiac remodeling. In order to do this research, first the procedures
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done to obtain these initial results must be altered in order to obtain better results which could
be quantified.
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ACCOMPLISHMENTS AND OUTPUT
I worked on parts of this project which qualitatively validated that FAP is produced in
infarcted hearts, including western blots, fluorescent staining, and BCA Assays. Through this
project and working in the lab, I learned about many cellular processes and to think critically
about how and why experiments worked or did not.
Through working on this research, I was able to apply for the Magellan Grant and was
lucky enough to be chosen as a recipient in 2015. Having this grant has allowed me to work on
this research with Dr. Goldsmith at the USC School of Medicine campus.
I was able to assist in presenting this research at the American Heart Association
Conference, in New Orleans, LA, in November of 2016. This research was published in the AHA
Circulation Journal, Volume 134 Issue 1. In April of 2017, I will be presenting a poster with this
research at Discover USC. In May of 2017, I will be graduating with honors from the SC Honors
College with Magna Cum Laude.
Working in this lab has allowed me to further define and explore both my research
interests as a Public Health major and pre-med student. This experience has also provided me
with the skills to critically analyze scientific publications, practice sterile techniques, and work
with cell culture. I have known for a long time that I want to pursue a career as a doctor, and I
will matriculate into the Medical University of South Carolina College of Medicine, Class of
2021, where I plan to pursue a specialty in surgery.
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Figure 14. Image of team at AHA conference

Figure 13. Image of team holding poster for AHA

Figure 15. Image of me at presentation of
poster at AHA conference
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